Blood Pressure in Heart Failure. A Love-Hate Relationship**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 49, Issue 1, 2007, Pages 40-42

  Pfeffer, Marc A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PRAZOSIN; VASODILATOR AGENT;

ANEURYSM RUPTURE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QRS COMPLEX; RISK FACTOR; RISK REDUCTION; STROKE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; VASODILATOR AGENTS;

EID: 33845867140     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.028     Document Type: Editorial

References (21)

1. Anand I.S., Tam S.W., Rector T.S., et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49 (2007) 32-39
2. Metropolitan Life Insurance Company. Blood Pressure: Insurance Experience and Its Implications (1961), Metropolitan Life Insurance Co, New York, NY
3. Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes III J., and The Framingham Study. Factors of risk in the development of coronary heart disease-six year follow-up experience. Ann Intern Med 55 (1961) 33-50
4. Stamler J., Stamler R., and Neaton J.D. Blood pressure, systolic and diastolic, and cardiovascular risks. U.S. population data. Arch Intern Med 153 (1993) 598-615
5. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002) 3068-3072
6. Veterans Administration Cooperative Study Group on Hypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202 (1967) 1028-1034
7. Veterans Administration Cooperative Study Group on Hypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213 (1970) 1143-1152
8. Psaty B.M., Lumley T., Furberg C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003) 2534-2544
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
10. Dahlöf B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., and Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338 (1991) 1281-1285
11. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 45 (2005) 813-827
12. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., and Boscardin W.J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
13. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
14. Morrow D.A., Antman E.M., Giugliano R.P., et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358 (2001) 1571-1575
15. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
16. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 (2006) 1424-1433
17. Cohn J., and Franciosa J. Vasodilator therapy of cardiac failure. N Engl J Med 297 (1977) 27-31 254-8
18. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
19. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
20. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
21. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057